Navigation Links
Stallergenes Inaugurates the Biggest Pharmaceutical Allergen Production Unit in the World
Date:9/10/2008

ANTONY, France, September 10 /PRNewswire-FirstCall/ -- Stallergenes S.A. officially inaugurates its new pharmaceutical production unit, located in the Paris area.

Designed to comply with the most stringent EMEA (European Medicines Agency) and FDA (US Food and Drug Administration) standards, this unit will produce desensitisation treatments for all markets, primarily in Europe and North America.

This investment worth more than 20 million euros will incorporate the production of the active substance for the Oralair(R) Grasses tablet and increase the production capacity for Staloral(R), to meet the needs of an expanding international marketplace.

"For Stallergenes, this investment marks a major step forward. This new production unit will help the company break into the tough U.S market and increase its production capacity tenfold," states Albert Saporta, Chairman and CEO of Stallergenes.

ABOUT ORALAIR(R) GRASSES

Oralair(R) Grasses is a fast-dissolving sublingual desensitisation tablet indicated in allergic rhino-conjunctivitis caused by grass pollen for patients with moderate to severe symptoms unsatisfied with or inadequately controlled by symptomatic treatments. Oralair(R) Grasses contains a mix of five standardised grass allergens, mimicking patients' natural exposure: perennial rye grass (Lolium perenne), meadow grass (Poa pratensis), timothy grass (Phleum pratense), cocksfoot (Dactylis glomerata) and sweet vernal grass (Anthoxanthum odoratum). In June 2008, Oralair(R) Grasses was granted a marketing authorisation in adults in Germany and a paediatric extension of its indications is expected by the end of the year. Stallergenes then plans to launch a mutual recognition procedure in the near future, with a view to marketing Oralair(R) Grasses in other European countries in both indications.

ABOUT Staloral(R)

Staloral(R) is an NPP (named patient product) sublingual solution (drops to be placed under the tongue) of allergen extracts. Staloral(R) is indicated in allergic rhino-conjunctivitis caused by pollen, dust mites, mould and dander (animal hair). Staloral(R) is available in the majority of European countries.

ABOUT STALLERGENES

Stallergenes is a European biopharmaceutical company dedicated to desensitisation therapies for the prevention and treatment of allergy-related respiratory diseases, e.g. rhino-conjunctivitis and allergic asthma. A pioneer and leader in sublingual desensitisation treatments, Stallergenes devotes 20% in raw data of its turnover to Research and Development and is actively involved in the development of a new therapeutic class: sublingual desensitisation tablets.

In 2007, Stallergenes had a turnover of 147 million euros and provided desensitisation treatments to more than 500,000 patients.

Stallergenes is listed on Euronext Paris (Compartment

B) and is part of the sample composing the SBF 120

index.

ISIN code: FR0000065674

Reuters code: GEN.PA

Bloomberg code: GEN.FP

To find out more, visit the website: http://www.stallergenes.com


'/>"/>
SOURCE Stallergenes
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Stallergenes: First Half Year 2008: A 19% Increase in Operating Profit and Net Profit
2. Stallergenes: Q2 2008 Sales up 18% Revision Upwards of 2008 Sales Growth
3. Stallergenes : Sublingual Desensitisation Tablets Oralair Grasses Approved in Germany
4. STALLERGENES : Further Profit Growth Acceleration of R&D Expenditure
5. STALLERGENES: 2007: A Further Year of Strong Growth: Up 16%
6. STALLERGENES and Protein eXpert Enter Into a Partnership for Producing Mites Recombinant Allergens
7. STALLERGENES: ORALAIR Grasses: Positive Results of VO52.06 Paediatric Study
8. Stallergenes : 3rd Quarter Sales Up 17%: 9- Month Cumulative Sales Up 17%
9. STALLERGENES : Strong Business Growth: +17% and Earnings Per Share up 30%
10. Eyeforpharmas Marketing Summit is shaping up to be the biggest event of its kind ever
11. Panacea Pharmaceuticals Lung Cancer Diagnostic Test, LC Detect(SM), Named One of Time Magazines Ten Biggest Medical Breakthroughs of 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016 Houston Methodist Willowbrook ... Cy-Fair Sports Association to serve as their official ... Houston Methodist Willowbrook will provide sponsorship support, athletic ... with association coaches, volunteers, athletes and families. ... Cy-Fair Sports Association and to bring Houston Methodist ...
(Date:6/23/2016)... YORK , June, 23, 2016  The Biodesign ... to envision new ways to harness living systems and ... Modern Art (MoMA) in New York City ... than 130 participating students, showcased projects at MoMA,s Celeste ... Paola Antonelli , MoMA,s senior curator of architecture ...
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample tracking software ... State Crime Laboratory, has joined STACS DNA as a Field Application Specialist. , ... Tremblay, President and COO of STACS DNA. “In further expanding our capacity as a ...
(Date:6/23/2016)...  Blueprint Bio, a company dedicated to identifying, protecting ... has closed its Series A funding round, according to ... "We have received a commitment from Forentis Fund that ... meet our current goals," stated Matthew Nunez . ... complete validation on the current projects in our pipeline, ...
Breaking Biology Technology:
(Date:3/31/2016)... 31, 2016   ... the "Company") LegacyXChange is excited to release ... soon to be launched online site for trading 100% ... ) will also provide potential shareholders a sense of ... to an industry that is notorious for fraud. The ...
(Date:3/29/2016)... 29, 2016 LegacyXChange, Inc. (OTC: ... and SelectaDNA/CSI Protect are pleased to announce our successful ... a variety of writing instruments, ensuring athletes signatures against ... collectibles from athletes on LegacyXChange will be assured of ... DNA. Bill Bollander , CEO states, ...
(Date:3/22/2016)... March 22, 2016 ... Sensors Market for Consumer Industry by Type (Image, ... Application (Communication & IT, Entertainment, Home Appliances, ... Forecast to 2022", published by MarketsandMarkets, the ... to reach USD 26.76 Billion by 2022, ...
Breaking Biology News(10 mins):